Health

  • March 03, 2026

    Death From Stem Cell Treatment For ALS Draws $24M Verdict

    A Washington state jury awarded $24 million to the family of a patient who died just two days after what his family members described as a "worthless" spinal cord procedure to treat his ALS at a Seattle stem cell clinic.

  • March 03, 2026

    Ex-FDA Leaders Rebut Contraception Rollbacks At 3rd Circ.

    Former FDA commissioners argued that Trump-era religious exemptions for birth control coverage jeopardize public health and distort medical science, in an animus brief filed Monday with the Third Circuit.

  • March 03, 2026

    FDA Targets Advertising For Knockoff Weight-Loss Meds

    The U.S. Food and Drug Administration on Tuesday accused about 30 telehealth companies of illegally marketing compounded weight-loss and diabetes drugs, the agency's latest salvo in a crackdown on direct-to-consumer pharmaceutical advertising.

  • March 03, 2026

    NC Doctor's Bid For New Trial Is Too Late, Judge Says

    A North Carolina federal judge has refused to order a new trial for a doctor convicted of participating in an $11 million Medicare fraud scheme, finding that because the motion did not contain new evidence, the deadline to request another trial has passed.

  • March 03, 2026

    Florida Man Pleads Guilty In $24M HIV Drugs Fraud Scheme

    The owner of a marketing company in Florida has pled guilty to receiving kickbacks as part of a $24 million scheme to sign up Medicare and Medicaid beneficiaries for HIV prophylactic medications they did not need.

  • March 03, 2026

    Wells Fargo Escapes Ex-Workers' Prescription Cost Suit

    Former Wells Fargo workers on the employer healthcare plan failed to show that the company violated federal benefits law by allowing them to overpay for prescription drugs, a Minnesota federal judge found Tuesday, tossing the proposed class action.

  • March 03, 2026

    Monthly Merger Review Snapshot

    The U.S. Department of Justice got its antitrust case against Live Nation and Ticketmaster teed up for trial, as a court continues mulling the department's settlement last year in a case challenging a deal by Hewlett Packard Enterprise, and lawmakers call for scrutiny of Paramount Skydance's blockbuster acquisition of Warner Bros. Discovery.

  • March 03, 2026

    States Can't Duck Regeneron Counterclaims In FCA Case

    Eleven states pursuing a False Claims Act case against Regeneron Pharmaceuticals over what they say were inflated reimbursements for an eye drug can't block counterclaims by the drugmaker on sovereign immunity grounds, a Massachusetts federal judge has ruled.

  • March 03, 2026

    4th Circ. Won't Revive Retired Miners' Health Fight

    The Fourth Circuit refused Tuesday to reopen a dispute over lifetime retirement health and life insurance benefits from a proposed class of retired coal miners, keeping in place a West Virginia federal court's judgment that broadly favored the company following a seven-day bench trial.

  • March 03, 2026

    Curaleaf Says No Private Info Leaked In Buyers' Data Suit

    Curaleaf Inc. is asking a Florida federal court to throw out a suit alleging that its website failed to protect buyers' personal and health information, saying none of the information the site or its software collects is personal property or healthcare information.

  • March 03, 2026

    Judge Won't Rely On DOJ 'Decency' In Trans Records Case

    A Pennsylvania federal judge blocked the U.S. Department of Justice from getting patient-specific records of gender-affirming care at the University of Pittsburgh Medical Center Children's Hospital, excoriating the government's request and its reasoning for demanding the data.

  • March 03, 2026

    1st Circ. Won't Revive Boston's Opioid Claims Against PBMs

    Boston lost its bid to revive opioid crisis-related claims against two pharmacy benefit managers, as a First Circuit panel affirmed that the suit came years too late.

  • March 03, 2026

    FTC Makes 'Significant Progress' In OptumRx, Caremark Talks

    Federal Trade Commission staffers got more time Tuesday for settlement talks with OptumRx and Caremark that could end the agency's case accusing the pharmacy benefit managers of inflating insulin prices, with staffers citing considerable progress in the weeks since inking a deal with Express Scripts.

  • March 03, 2026

    Fla. Billing Co. To Settle With Feds Over $15M Medicare Fraud

    The U.S. government has settled its False Claims Act lawsuit with a medical coding and billing business it accused of aiding a Miami-based laboratory in fraudulently billing Medicare for more than $15 million in genetic tests.

  • March 02, 2026

    High Court Blocks California's Gender Privacy Rule

    The U.S. Supreme Court on Monday reinstated a lower court order that barred California public schools from allowing transgender and gender-nonconforming students to use different names and pronouns at school without their parents' knowledge or consent while the order is appealed.

  • March 02, 2026

    E-Rate Could Cut Some Regulatory Fat, FCC Told

    While the Federal Communications Commission is looking for regulations to get rid of, one organization said it has a list of options for the agency to consider when it comes to the E-Rate subsidy program.

  • March 02, 2026

    Texas AG Says Gender Care Ban Includes Mental Health

    Mental-health professionals in Texas risk losing their licenses and public funding if they "facilitate" the gender-affirming care banned under state law, said an opinion issued Friday by Attorney General Ken Paxton, which calls them the "gatekeepers."

  • March 02, 2026

    Abbott Beats Data Sharing Suit Over Glucose Tracking Trial

    An Illinois federal judge on Monday permanently tossed a lawsuit accusing Abbott Laboratories of unlawfully sharing website visitors' personal data with Meta and Google, saying the plaintiffs can't plausibly show that their legally protected information ever left Abbott's website.

  • March 02, 2026

    Epic Must Face Price Conspiracy Claims Over Gallstone Drug

    Epic Pharma LLC must face the majority of suits by hospitals, insurers and other drug purchasers alleging it conspired to raise and control the price of gallstone medication ursodiol, a Pennsylvania federal judge ruled Monday.

  • March 02, 2026

    3rd Circ. Unsure Criticism Of Prof's DEI Stance Is Defamation

    A Third Circuit panel on Monday questioned whether the retraction of a former University of Pittsburgh program director's article criticizing diversity, equity and inclusion was a purely academic debate the courts should avoid, or if statements that it "misrepresented" facts were enough to sustain defamation claims.

  • March 02, 2026

    SEC Inks $200K Settlement In False PPE Press Release Suit

    The CEO and consultant of a consumer goods company will pay over $200,000 to settle the U.S. Securities and Exchange Commission's claims that they artificially inflated the company's share price by nearly 200% by disseminating a false press release at the beginning of the COVID-19 pandemic.

  • March 02, 2026

    Anthem Avoids Patients' Ghost Network Suit In NY

    A New York federal judge on Monday granted Anthem escape from a proposed class action from patients who alleged inaccuracies in the insurer's mental health provider directory violated New York state laws, holding their claims were preempted by federal employee health benefits law.

  • March 02, 2026

    NC Care Co. Operator Urges Judge To Ax Wage Verdict

    A North Carolina residential mental health company and its owner have urged a federal judge to nix a jury verdict finding that they underpaid workers, saying the employees relied on speculative evidence and a damages summary that was disclosed too late.

  • March 02, 2026

    6th Circ. Upholds 12-Year Stint For Mich. Doc In 'Pill Mill' Case

    The Sixth Circuit affirmed the convictions and 12-year prison sentence of a Michigan doctor accused of operating a cash-only "pill mill" that wrote thousands of opioid prescriptions, holding that the trial judge properly handled the jury instructions and key evidentiary rulings.

  • March 02, 2026

    Hagens Berman Denied Rehearing Bid In Sanctions Dispute

    The Third Circuit on Monday rejected plaintiffs firm Hagens Berman Sobol Shapiro LLP's request to reconsider weighing in on the sanctions dispute in a since-dropped product liability case that resulted in the trial court judge referring the firm for possible criminal investigation.

Expert Analysis

  • Key Trends For Life Sciences Cos. To Watch In 2026

    Author Photo

    Following a year of drastic change at the U.S. Food and Drug Administration, two themes are likely to drive the coming year — a commitment to lowering the cost of drugs and an inherent tension between the priorities of the health agencies and the broader administration, say attorneys at Sheppard Mullin.

  • Series

    Muay Thai Makes Me A Better Lawyer

    Author Photo

    Muay Thai kickboxing has taught me that in order to win, one must stick to one's game plan and adapt under pressure, just as when facing challenges by opposing counsel or judges, says Mark Schork at Feldman Shepherd.

  • The Next Pressure Point In Digital Health: Informed Consent

    Author Photo

    Two new federal digital health initiatives will usher in a new era where virtual care, software-enabled devices and home-based monitoring are integrated into care and reimbursement models, with the impact of shifting rules and opportunities felt most immediately in the context of informed consent, says Kimberly Chew at Husch Blackwell.

  • Series

    Law School's Missed Lessons: Intentional Career-Building

    Author Photo

    A successful legal career is built through intention: understanding expectations, assessing strengths honestly and proactively seeking opportunities to grow and cultivating relationships that support your development, say Erika Drous and Hillary Mann at Morrison Foerster.

  • 4 Trends Shaping Drug And Medical Device Law For 2026

    Author Photo

    2025 saw some significant legal developments with potential impact for drug and device manufacturers, ranging from growing skepticism in science and regulatory entities to new regulation of artificial intelligence, say attorneys at Faegre Drinker.

  • Key Trends In Healthcare Antitrust In 2025

    Author Photo

    The healthcare industry braced for significant antitrust enforcement shifts last year driven by a change in administration, and understanding the implications of these trends is critical for healthcare organizations' risk management and strategic decision-making in the year ahead, say attorneys at Michael Best.

  • The 5 Most Important Bid Protest Decisions Of 2025

    Author Photo

    In a shifting bid protest landscape, five decisions in 2025 from the Federal Circuit, the U.S. Court of Federal Claims and the U.S. Government Accountability Office that addressed bedrock questions about jurisdictional reach and the breadth of agency discretion are likely to have a lasting impact, say attorneys at Bradley Arant.

  • Food Industry Braces For MAHA And Other Challenges In 2026

    Author Photo

    After the Make America Healthy Again movement kept the U.S. Food and Drug Administration under pressure in 2025, actions in the food safety space are likely to continue this year, including updated Supplemental Nutrition Assistance Program dietary guidelines and processed food definitions, say attorneys at Wiley.

  • Preparing For Congressional Investigations In A Midterm Year

    Author Photo

    2026 will be a consequential year for congressional oversight as the upcoming midterm elections may yield bolder investigations and more aggressive state attorneys general coalitions, so companies should consider adopting risk management measures to get ahead of potential changes, say attorneys at Morgan Lewis.

  • A Meaningful Shift In FDA's Biosimilarity Analysis

    Author Photo

    The U.S. Food and Drug Administration's potential pivot away from routinely requiring comparative efficacy studies for interchangeable biosimilar applications would not lower regulatory standards, but instead allow applicants to allocate resources toward establishing more probative evidence, says Theodore Thompson at Stinson.

  • Employment Immigration Trends And Challenges For 2026

    Author Photo

    U.S. companies competing for global talent should brace for a turbulent 2026, with greater compliance burdens, higher costs and the probability of workforce disruptions at every stage of the immigration process, from visa petitions to work authorization renewals, say attorneys at Duane Morris.

  • Top 5 Antitrust Issues For In-House Counsel To Watch In 2026

    Author Photo

    With Trump administration enforcement policy having largely taken shape last year, antitrust issues that in-house counsel should have on the radar range from scrutiny of technology-assisted pricing to the return of merger remedies, say attorneys at Squire Patton.

  • 4 Developments That Defined The 2025 Ethics Landscape

    Author Photo

    The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.

  • Navigating AI In The Legal Industry

    Author Photo

    As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.

  • How Fractional GCs Can Manage Risks Of Engagement

    Author Photo

    As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.